Can We Offer Prenatal cfDNA Screening at Just 8 Weeks?

The Evolution of Early Prenatal Screening

Traditionally, clinicians initiate prenatal cfDNA screening only after 10 weeks of pregnancy. However, a landmark clinical trial shows that testing can safely begin much earlier. Specifically, the implementation of fetal fraction amplification (FFA) changes the landscape of early pregnancy management. This technology overcomes the historic barrier of low fetal fraction in maternal blood. Consequently, obstetricians can now offer highly reliable aneuploidy screening as early as 8 weeks of gestation.

The Challenge of Low Fetal Fraction in Early Gestation

Before this technological breakthrough, early screening frequently failed due to insufficient fetal DNA in the maternal bloodstream. Typically, labs require a fetal fraction of at least 4% to yield a reliable result. For instance, without amplification, nearly 4.8% of samples collected at 10 weeks demonstrate low fetal fraction. Furthermore, this rate rises dramatically at earlier gestational ages, particularly in patients with a high body mass index (BMI). Therefore, standard protocols historically restricted NIPT to 10 weeks or later.

Early Performance of prenatal cfDNA screening at 8 Weeks

To evaluate early screening, researchers conducted a prospective study enrolling 562 pregnant individuals. Ultimately, 470 patients completed two blood draws to compare results. The first draw occurred between 6 and 9 weeks, while the second occurred at 10 weeks or later. Additionally, researchers processed all samples using a cfDNA screen with fetal fraction amplification.

The study identified 7 3/7 weeks as the earliest age where the low fetal fraction rate remained below 4.8%. Moreover, the screen failure rate for samples drawn between 8 and 9 weeks was only 0.4%. Crucially, both positive and negative percent agreements reached 100% for all screened aneuploidies during this timeframe. Additionally, fetal sex call concordance was 100% for both male and female fetuses. Consequently, these findings confirm that fetal fraction amplification delivers robust clinical utility at 8 weeks.

Overcoming the BMI Barrier

Maternal obesity historically poses a major challenge for cell-free DNA screening because it dilutes the fetal fraction. Specifically, for patients with a BMI of 30 or higher, the median fetal fraction was 7.2% at 6-9 weeks. However, using fetal fraction amplification, this cohort still achieved highly reliable screening results. Indeed, the amplification technology successfully mitigated the low fetal fraction typically seen in obese patients. Consequently, clinicians can reliably offer early screening to patients regardless of their body mass index.

What This Means for Obstetric Practice

These findings have significant implications for routine prenatal care. First, enabling screening at 8 weeks allows parents to receive crucial genetic information much earlier in pregnancy. Additionally, early risk assessment facilitates timely decisions regarding invasive diagnostic procedures like chorionic villus sampling. Furthermore, reducing the anxiety associated with waiting for 10-week testing represents a major clinical benefit. Ultimately, integrating fetal fraction amplification into clinical workflows can optimize the prenatal screening pathway for both physicians and patients.

Frequently Asked Questions

Q1: What is fetal fraction amplification and how does it help?

Fetal fraction amplification is a technology that enriches the proportion of cell-free fetal DNA in a maternal blood sample. Consequently, this allows clinicians to perform accurate genetic testing at earlier gestational ages when natural fetal DNA is low.

Q2: Can prenatal cfDNA screening be performed on patients with a high BMI?

Yes, patients with a high BMI can successfully undergo early screening. Although obesity typically lowers the fetal fraction, fetal fraction amplification overcomes this challenge. Specifically, the study reported a median fetal fraction of 7.2% in obese patients at 6-9 weeks.

Q3: How accurate is early screening at 8 weeks of gestation?

The study showed excellent performance between 8 and 9 weeks of gestation. Specifically, researchers observed a very low screen failure rate of 0.4%. Additionally, they achieved 100% positive and negative percent agreements for all screened chromosomal aneuploidies.

References

1. Dugoff L et al. Prenatal Cell-Free DNA Screening With Fetal Fraction Amplification at 6-9 Weeks of Gestation. Obstet Gynecol. 2026 May 21. doi: 10.1097/AOG.0000000000006324. PMID: 42166774.
2. Jensen DK et al. Prenatal Cell-Free DNA Screening With Fetal Enrichment Enables Sampling From 8 Weeks of Gestational Age. Obstet Gynecol. 2025 Jul;146(1):12-18.